Evidence map›Paper›PMID 26307612›Full record

ArticleMolecular neurobiology2016

Expression Profile of MiR-128 in the Astrocytoma Patients and Cell Lines.

Jingjing Xu, Yuqiong Liu, Si Guo, Shengli Ma, Lin Xiao, Na Wei, Rui Xue

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular neurobiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Jingjing XuDepartment of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yuqiong LiuDepartment of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Si GuoClinical Laboratory, Henan Provincial People's Hospital, 7 Wei Wu Road, Zhengzhou, 450000, China.
Shengli MaEmergency Department, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Lin XiaoDepartment of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Na WeiDepartment of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Rui XueDepartment of Urology, The First Affiliated Hospital of Zhengzhou University, No. 1 Jian She Dong Avenue, Zhengzhou, 450002, People's Republic of China. ruixue1715@126.com.
First Affiliated Hospital of Zhengzhou University · CNHenan Provincial People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malignant astrocytomas are the most common primary brain tumors. The critical characterizes of astrocyomas are their aggressive and infiltrative in the brain, which leads to uncontrollable by conventional forms of therapy. MicroRNAs are small RNAs that had been found to regulate their targets by specific binding to the 3'-untranslated region (3'UTR) of mRNA. Recent advances in understanding the molecular biology of these tumors have revealed that microRNA (miRNA) disruption may play important roles in the pathogenesis of astrocytomas. And some of the miRNA alterations were found in the serum of astrocytoma patients. In this study, we studied the expression profile of miR-128, in the different stages of astrocytoma tissues and two human astrocytoma cell lines, A172 and T98G cells. We found that the levels of miR-128 are decreased in the A172 and T98G cells when compared to normal human astrocyte (NHA). Furthermore, the levels of miR-128 decreased gradually to the pathological stages of astrocytomas. We also identified that TROVE2 is a novel target of miR-128 by the luciferase reporter system. Furthermore, the expression levels of TROVE2 are dramatically increased with the pathological stages increasing. Finally, the levels of TROVE2 are negatively correlated with miR-128 in astrocytoma tissues. Our data provided novel evidence for the miR-128 and TROVE2 in the development of human astrocytomas.

Indexed as

AstrocytomaAutoantigensBrain NeoplasmsCell Line, TumorHEK293 CellsHumansMicroRNAsNeoplasm GradingRibonucleoproteinsRNA, Small CytoplasmicSS-A AntigenTranscriptomeAutoantigensMicroRNAsMIRN128 microRNA, humanRibonucleoproteinsRNA, Small CytoplasmicRO60 protein, humanSS-A AntigenAstrocytomasGradesMiR-128mRNATROVE2

Identifiers

PMID26307612
OpenAlexW1143401694

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.